Braftovi (Encorafenib)

Braftovi is a kinase inhibitor used:

• in combination with medicine binimetinib (Mektovi), to treat patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
• in combination with medication cetuximab (Erbitux), to treat adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy.

Note: Braftovi (Encorafenib 75 mg) is not for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC. 

Recommended Dosage: Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting treatment with Braftovi. 

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma: The recommended dosage is 450 mg (six 75 mg capsules) orally once daily along with medicine binimetinib until the disease is progressive or unacceptable toxicity occurs.

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC): The recommended dosage is 300 mg (four 75 mg capsules) orally once daily along with cetuximab until the disease is progressive or unacceptable toxicity occurs. 

Braftovi capsules may be taken with or without food. Do not take a missed dose within 12 hours of the next dose of Braftovi. Do not take any additional dose if vomiting occurs after the administration of this medication but continue with the very next scheduled dose.

• New primary malignancies, non-cutaneous and cutaneous, may emerge in those treated with BRAF inhibitors and can emerge with Encorafenib.
• In the trial, cutaneous squamous cell carcinoma (cuSCC), including keratoacanthoma (KA), and basal cell carcinoma occurred in those who received Encorafenib along with binimetinib. Perform dermatologic evaluations before starting treatment, every 2 months during treatment, and for up to 6 months following interruption of treatment.
• Based on its working, braftovi 75 mg capsule may promote malignancies linked with activation of RAS through mutation or other mechanisms. Assess those receiving this medicine for signs and symptoms of non-cutaneous malignancies. Interrupt treatment for RAS mutation-positive non-cutaneous malignancies. 
• In vitro experiments have shown paradoxical activation of MAP-kinase signaling and enhanced cell proliferation in BRAF wild-type cells, which are exposed to BRAF inhibitors. Confirm the existence of BRAF V600E/V600K mutation before starting treatment. 
• Uveitis, including iridocyclitis and iritis, may occur in those treated with Braftovi 75 mg capsule along with binimetinib. Assess for visual signs/symptoms at each visit. Ophthalmologic evaluation needs to be performed at regular intervals. Withhold, reduce dose, or permanently interrupt on behalf of the severity of adverse reaction. 
• Encorafenib is linked with dose-dependent QTc interval prolongation in specific patients. Monitor those who already have or who are at increased risk of developing QTc prolongation. Assess and manage hypomagnesemia/hypokalemia prior to and during administration of Encorafenib.
• Braftovi when used as a single agent is linked with an increased probability of certain side effects compared to when Braftovi is used along with binimetinib. If medication binimetinib is temporarily interrupted or permanently interrupted, reduce the dose as recommended. 
• Mechanism of action suggests that Braftovi can cause fetal harm if administered to a pregnant woman. Females of reproductive age should use an effective, non-hormonal method of contraception since Braftovi can render hormonal contraceptives ineffective, during therapy and for 14 days after the final dose.

What documents are required to import BRAFTOVI to India?

BRAFTOVI (encorafenib) capsules can be imported by patients or government hospitals on behalf of patients.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s Identity Proof (issued by the Government of India).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from a doctor.
• Import permit if applicable.

Is BRAFTOVI available in India?

BRAFTOVI (encorafenib capsules) is a prescription pharmaceutical drug that legally requires a medical prescription to be dispensed. Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability of Braftovi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.).
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

BRAFTOVI can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of BRAFTOVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Braftovi 75 mg price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing Krazati from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Braftovi®?

Encorafenib is the Generic Name for the trade name drug Braftovi®.

What is the Manufacturer’s Name of Braftovi®?

Braftovi® is manufactured by Pfizer Inc.

Is Braftovi® approved by the FDA?

Yes, Braftovi® is approved by the FDA. Date of first/initial approval: June 27, 2018.

Where can I get Braftovi® at the best price in India?

To get the best Braftovi capsule price in India, contact Urgent Meds (a WHO-GDP & ISO 9001:2008 authorized company). A medical prescription is required while buying Braftovi®.

What is the dosage and form of Braftovi® supplied?

Braftovi® is supplied as Capsules: 75 mg for oral administration.

What are the most common side effects of Braftovi® in combination with binimetinib?

The most common side effects of Braftovi® in combination with binimetinib are fatigue, abdominal pain, nausea, vomiting, and arthralgia.

What are the most common side effects of Braftovi® in combination with cetuximab?

The most common side effects of Braftovi® in combination with cetuximab are diarrhea, dermatitis acneiform, fatigue, nausea, abdominal pain, decreased appetite, rash, and arthralgia.

How much does Braftovi® cost in India?

Braftovi® cost in India is less and can vary. In order to buy or procure this kinase inhibitor authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Braftovi®?

Store at 20-25°C (68-77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Do not use it if the safety seal under the cap is broken/missing. Dispense in the original bottle. Avoid removing the desiccant. Protect from moisture. Keep the container tightly closed.

Is it safe to buy Braftovi® online from India?

Yes, you can buy Braftovi® capsules in India online at the best price from Urgent Meds if Braftovi® has not been approved or is not available in your country.